Biscayne NeuroTherapeutics
Miami
About Biscayne NeuroTherapeutics
Biscayne Neurotherapeutics is a clinical-stage biotechnology company developing novel therapies for difficult-to-treat neurological disorders. Biscayne’s lead compound, BIS-001, is in clinical development for the treatment of refractory forms of epilepsy. Biscayne Neurotherapeutics has an experienced executive team with an extensive track record of successful drug development, and its scientific advisors include a number of highly respected experts studying seizure and other CNS disorders. The company is headquartered in Miami, Florida, and benefits from the growing entrepreneurial South Florida biomedical sector.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.0M
- Funding stage: M&A
- Last round: Series B (Jan 2017)
- Website: biscayneneuro.com
- Phone: 212 584-2276
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/biscayne-neurotherapeutics-193400 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.